Idiopathic pulmonary fibrosis and lung cancer: A clinical and pathogenesis update

Current Opinion in Pulmonary Medicine

Volumn 21, Issue 6, 2015, Pages 626-633

  Antoniou, Katerina M ^a,b   Tomassetti, Sara ^c   Tsitoura, Eliza ^b   Vancheri, Carlo ^d  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

^c MORGAGNI PIERANTONI HOSPITAL   (Italy)

^d UNIVERSITY OF CATANIA   (Italy)

Author keywords

Common epigenetic marks in idiopathic pulmonary fibrosis and cancer; epigenetics; idiopathic pulmonary fibrosis; lung cancer

Indexed keywords

ANTIFIBROTIC AGENT; ANTINEOPLASTIC AGENT; DNA; DNA METHYLTRANSFERASE; MICRORNA; MICRORNA 29; NINTEDANIB; PIRFENIDONE; TELOMERASE; TRICHOSTATIN A; VORINOSTAT;

CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CELL HYPOXIA; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DNA METHYLATION; DRUG EFFICACY; DRUG SAFETY; EPIGENETICS; FIBROSING ALVEOLITIS; HUMAN; LUNG CANCER; LUNG CARCINOGENESIS; LUNG RESECTION; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PATHOGENESIS; PREVALENCE; PROSPECTIVE STUDY; REVIEW; RISK FACTOR; SQUAMOUS CELL LUNG CARCINOMA; ANIMAL; COMPLICATION; GENETIC EPIGENESIS; IDIOPATHIC PULMONARY FIBROSIS; INCIDENCE; LUNG NEOPLASMS; PATHOLOGY;

ANIMALS; EPIGENESIS, GENETIC; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INCIDENCE; LUNG NEOPLASMS; PREVALENCE; RISK FACTORS;

EID: 84942435784     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0000000000000217     Document Type: Review

References (88)

1. Kreuter M, Ehlers-Tenenbaum S, Schaaf M, et al. Treatment and outcome of lung cancer in idiopathic interstitial pneumonias. Sarcoidosis Vasc Diffuse Lung Dis 2015; 31:266-274.
2. Vancheri C. Common pathways in idiopathic pulmonary fibrosis and cancer. Eur Respir Rev 2013; 22:265-272.
3. Le Jeune I, Gribbin J, West J, et al. The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK. Respir Med 2007; 101:2534-2540.
4. Matsushita H, Tanaka S, Saiki Y, et al. Lung cancer associated with usual interstitial pneumonia. Pathol Int 1995; 45:925-932.
5. Turner-Warwick M, Lebowitz M, Burrows B, et al. Cryptogenic fibrosing alveolitis and lung cancer. Thorax 1980; 35:496-499.
6. Daniels CE, Jett JR. Does interstitial lung disease predispose to lung cancer? Curr Opin Pulm Med 2005; 11:431-437.
7. Tomassetti S, Gurioli C, Ryu JH, et al. The impact of lung cancer on survival of idiopathic pulmonary fibrosis. Chest 2015; 147:157-164.
8. Ozawa Y, Suda T, Naito T, et al. Cumulative incidence of and predictive factors for lung cancer in IPF. Respirology 2009; 14:723-728.
9. Aubry MC, Myers JL, Douglas WW, et al. Primary pulmonary carcinoma in patients with idiopathic pulmonary fibrosis. Mayo Clin Proc 2002; 77:763-770.
10. Hubbard R, Venn A, Lewis S, et al. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med 2000; 161:5-8.
11. Cottin V, Nunes H, Brillet PY, et al. Combined pulmonary fibrosis and emphysema: A distinct underrecognised entity. Eur Respir J 2005; 26:586-593.
12. Usui K, Tanai C, Tanaka Y, et al. The prevalence of pulmonary fibrosis combined with emphysema in patients with lung cancer. Respirology 2011; 16:326-331.
13. Kishi K, Homma S, Kurosaki A, et al. High-resolution computed tomography findings of lung cancer associated with idiopathic pulmonary fibrosis. J Comput Assist Tomogr 2006; 30:95-99.
14. Park J, Kim DS, Shim TS, et al. Lung cancer in patients with idiopathic pulmonary fibrosis. Eur Respir J 2001; 17:1216-1219.
15. Fujimoto T, Okazaki T, Matsukura T, et al. Operation for lung cancer in patients with idiopathic pulmonary fibrosis: surgical contraindication? Ann Thorac Surg 2003; 76:1674-1678; discussion 1679.
16. Kushibe K, Kawaguchi T, Takahama M, et al. Operative indications for lung cancer with idiopathic pulmonary fibrosis. Thorac Cardiovasc Surg 2007; 55:505-508.
17. Watanabe A, Higami T, Ohori S, et al. Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis? J Thorac Cardiovasc Surg 2008; 136:1357-1363; 1363.e1-2.
18. Omori T, Tajiri M, Baba T, et al. Pulmonary resection for lung cancer in patients with idiopathic interstitial pneumonia. Ann Thorac Surg 2015. [Epub ahead of print]
19. Kumar P, Goldstraw P, Yamada K, et al. Pulmonary fibrosis and lung cancer: risk and benefit analysis of pulmonary resection. J Thorac Cardiovasc Surg 2003; 125:1321-1327.
20. Takeda A, Enomoto T, Sanuki N, et al. Acute exacerbation of subclinical idiopathic pulmonary fibrosis triggered by hypofractionated stereotactic body radiotherapy in a patient with primary lung cancer and slightly focal honeycombing. Radiat Med 2008; 26:504-507.
21. Minegishi Y, Sudoh J, Kuribayasi H, et al. The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced nonsmall cell lung cancer with idiopathic interstitial pneumonias. Lung Cancer 2011; 71:70-74.
22. Isobe K, Hata Y, Sakamoto S, et al. Clinical characteristics of acute respiratory deterioration in pulmonary fibrosis associated with lung cancer following anticancer therapy. Respirology 2010; 15:88-92.
23. Kenmotsu H, Naito T, Kimura M, et al. The risk of cytotoxic chemotherapyrelated exacerbation of interstitial lung disease with lung cancer. J Thorac Oncol 2011; 6:1242-1246.
24. Watanabe N, Taniguchi H, Kondoh Y, et al. Chemotherapy for extensive-stage small-cell lung cancer with idiopathic pulmonary fibrosis. Int J Clin Oncol 2014; 19:260-265.
25. Watanabe N, Taniguchi H, Kondoh Y, et al. Efficacy of chemotherapy for advanced nonsmall cell lung cancer with idiopathic pulmonary fibrosis. Respiration 2013; 85:326-331.
26. Armanios M. Telomeres and age-related disease: how telomere biology informs clinical paradigms. J Clin Invest 2013; 123:996-1002.
27. Miura Y, Saito T, Tsunoda Y, et al. Clinical effect of pirfenidone on incidence of lung carcinoma in chronic interstitial pneumonia. Eur Respir J 2014; 44 (Suppl 58):P3497.
28. Iwata T, Yoshida S, Nagato K, et al. Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis. Surg Today 2014. [Epub ahead of print]
29. Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated nonsmall-cell lung cancer (LUME-Lung 1): A phase 3, double-blind, randomised controlled trial. Lancet Oncol 2014; 15:143-155.
30. Grimminger F, Gunther A, Vancheri C. The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis. Eur Respir J 2015; 45:1426-1433.
31. Illingworth RS, Bird AP. CpG islands: a rough guide. FEBS Lett 2009; 583:1713-1720.
32. Hirasawa R, Chiba H, Kaneda M, et al. Maternal and zygotic DNMT1 are necessary and sufficient for the maintenance of DNA methylation imprints during preimplantation development. Genes Dev 2008; 22:1607-1616.
33. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002; 16:6-21.
34. Tang M, Xu W, Wang Q, et al. Potential of DNMT and its epigenetic regulation for lung cancer therapy. Curr Genomics 2009; 10:336-352.
35. Selman M, Pardo A. Stochastic age-related epigenetic drift in the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2014; 190:1328-1330.
36. Langevin SM, Pinney SM, Leung YK, et al. Does epigenetic drift contribute to age-related increases in breast cancer risk? Epigenomics 2014; 6:367-369.
37. Huidobro C, Fernandez AF, Fraga MF. Aging epigenetics: causes and consequences. Mol Aspects Med 2013; 34:765-781.
38. Armanios M. Telomerase and idiopathic pulmonary fibrosis. Mutat Res 2012; 730:52-58.
39. Hiyama E, Hiyama K. Clinical utility of telomerase in cancer. Oncogene 2002; 21:643-649.
40. Antoniou K, Samara K, Lasithiotaki I, et al. Differential telomerase expression in idiopathic pulmonary fibrosis and nonsmall cell lung cancer. Oncol Rep 2013; 30:2617-2624.
41. Yang IV, Pedersen BS, Rabinovich E, et al. Relationship of DNA methylation and gene expression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2014; 190:1263-1272.
42. Rabinovich EI, KapetanakiMG, Steinfeld I, et al.Global methylation patterns in idiopathic pulmonary fibrosis. PLoS One 2012; 7:e33770.
43. Sanders YY, Ambalavanan N, Halloran B, et al. Altered DNA methylation profile in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 186:525-535.
44. Subramaniam D, Thombre R, Dhar A, et al. DNA methyltransferases: A novel target for prevention and therapy. Front Oncol 2014; 4:80.
45. Comer BS, Ba M, Singer CA, et al. Epigenetic targets for novel therapies of lung diseases. Pharmacol Ther 2015; 147:91-110.
46. Ehrlich M. DNA hypomethylation in cancer cells. Epigenomics 2009; 1:239-259.
47. Kanwal R, Gupta S. Epigenetic modifications in cancer. Clin Genet 2012; 81:303-311.
48. Langevin SM, Kratzke RA, Kelsey KT. Epigenetics of lung cancer. Transl Res 2015; 165:74-90.
49. Belinsky SA. Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer. Carcinogenesis 2005; 26:1481-1487.
50. Lung HL, Bangarusamy DK, Xie D, et al. THY1 is a candidate tumour suppressor gene with decreased expression in metastatic nasopharyngeal carcinoma. Oncogene 2005; 24:6525-6532.
51. Schmidt B, Liebenberg V, Dietrich D, et al. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspirates. BMC Cancer 2010; 10:600.
52. Cisneros J, Hagood J, Checa M, et al. Hypermethylation-mediated silencing of p14(ARF) in fibroblasts from idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2012; 303:L295-L303.
53. Huang SK, Scruggs AM, McEachin RC, et al. Lung fibroblasts from patients with idiopathic pulmonary fibrosis exhibit genome-wide differences in DNA methylation compared to fibroblasts from nonfibrotic lung. PLoS One 2014; 9:e107055.
54. You L, Chen L, Pan L, et al. Zinc finger protein 467 regulates Wnt signaling by modulating the expression of sclerostin in adipose derived stem cells. Biochem Biophys Res Commun 2015; 456:598-604.
55. Sanders YY, Kumbla P, Hagood JS. Enhanced myofibroblastic differentiation and survival in Thy-1() lung fibroblasts. Am J Respir Cell Mol Biol 2007; 36:226-235.
56. Huang SK, Fisher AS, Scruggs AM, et al. Hypermethylation of PTGER2 confers prostaglandin E2 resistance in fibrotic fibroblasts from humans and mice. Am J Pathol 2010; 177:2245-2255.
57. Tzouvelekis A, Kaminski N. Epigenetics in idiopathic pulmonary fibrosis. Biochem Cell Biol 2015; 93:159-170.
58. Yang IV, Schwartz DA. Epigenetics of idiopathic pulmonary fibrosis. Transl Res 2015; 165:48-60.
59. Maecker HL, Yun Z, Maecker HT, et al. Epigenetic changes in tumor Fas levels determine immune escape and response to therapy. Cancer Cell 2002; 2:139-148.
60. Yang WY, Gu JL, Zhen TM. Recent advances of histone modification in gastric cancer. J Cancer Res Ther 2014; (10 Suppl):240-245.
61. Sanders YY, Hagood JS, Liu H, et al. Histone deacetylase inhibition promotes fibroblast apoptosis and ameliorates pulmonary fibrosis in mice. Eur Respir J 2014; 43:1448-1458.
62. Davies ER, Haitchi HM, Thatcher TH, et al. Spiruchostatin A inhibits proliferation and differentiation of fibroblasts from patients with pulmonary fibrosis. Am J Respir Cell Mol Biol 2012; 46:687-694.
63. Coward WR, Feghali-Bostwick CA, Jenkins G, et al. A central role for G9a and EZH2 in the epigenetic silencing of cyclooxygenase-2 in idiopathic pulmonary fibrosis. FASEB J 2014; 28:3183-3196.
64. Huang SK, Scruggs AM, Donaghy J, et al. Histone modifications are responsible for decreased Fas expression and apoptosis resistance in fibrotic lung fibroblasts. Cell Death Dis 2013; 4:e621.
65. Zhang X, Liu H, Hock T, et al. Histone deacetylase inhibition downregulates collagen 3A1 in fibrotic lung fibroblasts. Int J Mol Sci 2013; 14:19605-19617.
66. Sanders YY, Tollefsbol TO, Varisco BM, et al. Epigenetic regulation of thy-1 by histone deacetylase inhibitor in rat lung fibroblasts. Am J Respir Cell Mol Biol 2011; 45:16-23.
67. Guan P, Yin Z, Li X, et al. Meta-Analysis of human lung cancer microRNA expression profiling studies comparing cancer tissues with normal tissues. J Exp Clin Cancer Res 2012; 31:54.
68. Vosa U, Vooder T, Kolde R, et al. Meta-Analysis of microRNA expression in lung cancer. Int J Cancer 2013; 132:2884-2893.
69. Pandit KV, Milosevic J, Kaminski N. MicroRNAs in idiopathic pulmonary fibrosis. Transl Res 2011; 157:191-199.
70. Yang M, Shen H, Qiu C, et al. High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in nonsmall cell lung cancer. Eur J Cancer 2013; 49:604-615.
71. Liu G, Friggeri A, Yang Y, et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med 2010; 207:1589-1597.
72. Yang G, Yang L, Wang W, et al. Discovery and validation of extracellular/circulating microRNAs during idiopathic pulmonary fibrosis disease progression. Gene 2015; 562:138-144.
73. Kolenda T, Przybyla W, Teresiak A, et al. The mystery of let-7d-A small RNA with great power. Contemp Oncol (Pozn) 2014; 18:293-301.
74. Huleihel L, Ben-Yehudah A, Milosevic J, et al. Let-7d microRNA affects mesenchymal phenotypic properties of lung fibroblasts. Am J Physiol Lung Cell Mol Physiol 2014; 306:L534-L542.
75. Pandit KV, Corcoran D, Yousef H, et al. Inhibition and role of let-7d in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2010; 182:220-229.
76. Yang S, Banerjee S, de Freitas A, et al. Participation of miR-200 in pulmonary fibrosis. Am J Pathol 2012; 180:484-493.
77. Eades G, Yao Y, Yang M, et al. miR-200a regulates SIRT1 expression and epithelial to mesenchymal transition (EMT)-like transformation in mammary epithelial cells. J Biol Chem 2011; 286:25992-26002.
78. Bodempudi V, Hergert P, Smith K, et al. miR-210 promotes IPF fibroblast proliferation in response to hypoxia. Am J Physiol Lung Cell Mol Physiol 2014; 307:L283-L294.
79. Tsai YP, Wu KJ. Epigenetic regulation of hypoxia-responsive gene expression: focusing on chromatin and DNA modifications. Int J Cancer 2014; 134:249-256.
80. Dang K, Myers KA. The role of hypoxia-induced miR-210 in cancer progression. Int J Mol Sci 2015; 16:6353-6372.
81. Cushing L, Kuang PP, Qian J, et al. miR-29 is a major regulator of genes associated with pulmonary fibrosis. Am J Respir CellMol Biol 2011; 45:287-294.
82. Fabbri M, Garzon R, Cimmino A, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A 2007; 104:15805-15810.
83. Morita S, Horii T, Kimura M, et al. miR-29 represses the activities of DNA methyltransferases and DNA demethylases. Int J Mol Sci 2013; 14:14647-14658.
84. Williams AE, Moschos SA, Perry MM, et al. Maternally imprinted microRNAs are differentially expressed during mouse and human lung development. Dev Dyn 2007; 236:572-580.
85. Wang H, Guan X, Tu Y, et al. MicroRNA-29b attenuates nonsmall cell lung cancer metastasis by targeting matrix metalloproteinase 2 and PTEN. J Exp Clin Cancer Res 2015; 34:59.
86. Li J, Yang S, Yan W, et al. MicroRNA-19 triggers epithelial-mesenchymal transition of lung cancer cells accompanied by growth inhibition. Lab Invest 2015; 95:1056-1070.
87. Olive V, Li Q, He L. mir-17-92: A polycistronic oncomir with pleiotropic functions. Immunol Rev 2013; 253:158-166.
88. Dakhlallah D, Batte K, Wang Y, et al. Epigenetic regulation of miR-17-92 contributes to the pathogenesis of pulmonary fibrosis. Am J Respir Crit Care Med 2013; 187:397-405.